Machine signal
Active cluster sell — 3 distinct insiders, $1.3M, window ends Oct 2, 2026.
Figures computed from official regulatory filings — .
Analysttarget 33.93 USD (+48%) · consensus 4.5/5 · 13 buy · 1 hold · 0 sell
Ownershipinsiders 1.08% · institutions 114.87% · short 17.5% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Nurix Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
192 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Ring Christine | Sell | $134.1K | SEC |
| Ring Christine | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ring Christine | Exercise | $50.5K | SEC |
| Ring Christine | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ring Christine | Exercise | $50.5K | SEC |
| Ring Christine | Sell | $10.7K | SEC |
| Ring Christine | Sell | $138.4K | SEC |
| Hansen Gwenn | Sell | $37K | SEC |
| Hansen Gwenn | Exercise | $2.7K | SEC |
| Hansen Gwenn | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hansen Gwenn | Sell | $35.8K | SEC |
| Hansen Gwenn | Sell | $108.9K | Unusual size | SEC |
| Hansen Gwenn | Exercise | $8.1K | SEC |
| Hansen Gwenn | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hansen Gwenn | Sell | $64.3K | SEC |
| van Houte Hans | Sell | $73.1K | SEC |
| van Houte Hans | Sell | $42.9K | SEC |
| Ring Christine | Sell | $382.4K | SEC |
| Ring Christine | Exercise | $50.5K | SEC |
| Ring Christine | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| van Houte Hans | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hansen Gwenn | Sell | $90K | SEC |
| Hansen Gwenn | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ring Christine | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| van Houte Hans | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |